Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schoemaker

Showing results (1111-1120 of 1,161) with videos related to

Pageof 117
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 7, 2022
Incorporating progesterone receptor expression into the PREDICT breast prognostic modelIsabelle Grootes, Renske Keeman, Fiona M Blows, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Scientific Reports|October 6, 2021
Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosisMaria Escala-Garcia, Sander Canisius, Renske Keeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Cancer Causes & Control : CCC|April 8, 2016
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestryZhiguo Zhao, Wanqing Wen, Kyriaki Michailidou, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Human Mutation|February 21, 2018
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicityMara Colombo, Irene Lòpez-Perolio, Huong D Meeks, et al.
American Journal of Human Genetics|September 20, 2016
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 RegulationMaya Ghoussaini, Juliet D French, Kyriaki Michailidou, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Research Square|November 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaDale Garsed, Tibor Zwimpfer, Sian Fereday, et al.
Pageof 117

Showing results (1111-1120 of 1,161) with videos related to

Sort By:
Pageof 117
European Journal of Cancer (Oxford, England : 1990)|August 7, 2022
Incorporating progesterone receptor expression into the PREDICT breast prognostic modelIsabelle Grootes, Renske Keeman, Fiona M Blows, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Scientific Reports|October 6, 2021
Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosisMaria Escala-Garcia, Sander Canisius, Renske Keeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Cancer Causes & Control : CCC|April 8, 2016
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestryZhiguo Zhao, Wanqing Wen, Kyriaki Michailidou, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Human Mutation|February 21, 2018
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicityMara Colombo, Irene Lòpez-Perolio, Huong D Meeks, et al.
American Journal of Human Genetics|September 20, 2016
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 RegulationMaya Ghoussaini, Juliet D French, Kyriaki Michailidou, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Research Square|November 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaDale Garsed, Tibor Zwimpfer, Sian Fereday, et al.
Pageof 117